Skip to main content

Peer Review reports

From: Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

Original Submission
23 Jun 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
25 Aug 2023 Reviewed Reviewer Report
16 Oct 2023 Reviewed Reviewer Report
30 Oct 2023 Author responded Author comments - Xiaojia Wang
Resubmission - Version 4
30 Oct 2023 Submitted Manuscript version 4
Publishing
14 Dec 2023 Editorially accepted
2 Jan 2024 Article published 10.1186/s12885-023-11764-8

You can find further information about peer review here.

Back to article page